PRESS RELEASE ARCADIS RECEIVES SECOND UNSOLICITED PROPOSAL FROM WSP AFTER HAVING REJECTED AN EARLIER UNSOLICITED PROPOSAL, WHICH FUNDAMENTALLY UNDERVALUED THE COMPANY AND ITS FUTURE PROSPECTS Amsterdam, July 24 2026 – Arcadis (EURONEXT: ARCAD), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, confirms that it has received – after the Reuters article yesterday – a second unsolicited, conditional and non-binding proposal from WSP Global Inc. (“WSP”) regarding a potential offer for all issued and outstanding shares of Arcadis at a price of €51.5 per share in cash and WSP stock. WSP made a first proposal of €48.5 per share, of which a significant portion was WSP stock. This proposal was carefully reviewed...

UAB Urbo bankas (hereinafter – the Bank), juridinio asmens kodas 112027077, adresas: Konstitucijos pr. 18B, Vilnius. The Bank hereby informs that, following the receipt of permission from the Director of the Prudential Supervision Department of the Bank of Lithuania, dated 19 June 2026, to repurchase its issued Common Equity Tier 1 capital instruments (own shares) in accordance with the terms approved by the resolution of the General Meeting of Shareholders held on 27 March 2026, an own-share repurchase transaction was concluded on 23 July 2026. Under this transaction, the Bank acquired 3.26% (3,846,153 units) of the Bank’s shares from its shareholder “Western Petroleum Limited”. Following the transaction, the composition of the Bank’s shareholders remains unchanged. The Bank’s principal shareholder continues to be Konstantinas Karosas,...

Following the announcement of changes to Inbank’s operating model on 19 June 2026, the Inbank Supervisory Board has resolved to appoint Marten Meikop as Chief Technology Officer (CTO) and member of the Management Board, effective 10 August 2026. In addition, the Supervisory Board has resolved to extend the term of Chief Risk Officer Evelin Lindvers for a further three years starting 7 August 2026, and to recall Ivar Kurvits from the Management Board effective 31 July 2026. Ivar will continue as Head of Corporate Development & Strategy. Priit Põldoja, Chairman of the Management Board and CEO, comments: “I am delighted to welcome Marten to Inbank. He brings extensive experience in building cross-border technology platforms and leading large engineering organisations through periods of rapid growth. One of Marten’s key priorities...

Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews Paris, July 24, 2026. Sanofi today announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis (AD). This decision not to submit for global regulatory reviews was made as part of an ongoing strategic assessment of the pipeline. Sanofi has determined that the totality of efficacy and safety evidence generated to date does not support further development of amlitelimab in AD. While the ESTUARY phase 3 long-term extension study (clinical study identifier: NCT06407934) showed long-term maintenance of clinical response without relapse in patients aged 12 years and older with moderate-to-severe AD and an emerging safety profile that builds on previous data,...

PARIS, FRANCE, 24 JULY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III BOLD trial evaluating Bylvay versus placebo for patients living with biliary atresia (BA) who have already undergone a Kasai hepatoportoenterostomy (HPE) did not meet the primary endpoint of improvement in native liver survival vs placebo. Current topline data is in line with the well-established safety profile of odevixibat in approved indications. Characterized as a rapidly progressive and complex condition, BA is the leading cause of paediatric liver transplant, with no approved therapeutic options beyond Kasai HPE or liver transplant surgery. “Biliary atresia is a rare and serious liver disease that affects babies. Progressing rapidly and with no effective medical treatments, many children develop severe liver damage and biliary...

Key project development milestone achieved for ANM Process No. 866.035/2009 VANCOUVER, British Columbia, July 23, 2026 (GLOBE NEWSWIRE) — Resouro Strategic Metals Inc. (TSXV: RSM, ASX: RAU, OTCQB: RSGOF, FSE: 8TX) (“Resouro” or the “Company”) has marked a further step in the advancement of the Novo Mundo Gold Project (“Novo Mundo”) in Mato Grosso, Brazil. Its wholly owned Brazilian subsidiary, Ison do Brasil Mineração Ltda., successfully lodged the Mining Concession Application (Requerimento de Lavra) for ANM Process No. 866.035/2009 on 16 July 2026 . “Lodging of the Mining Concession Application is a key regulatory step toward converting our trial mining operation at Novo Mundo into a fully licensed, long-term producing asset,” said Christopher Eager, Resouro’s Chief Executive Officer. “It reflects...

SHANGHAI, July 23, 2026 (GLOBE NEWSWIRE) — FREELANDER has announced the unveiling of FREELANDER 8’s intelligent cabin details, as preparations for its Middle East regional launch in Abu Dhabi are underway. As a British Premium Intelligent All-Terrain brand, FREELANDER continues to pioneer new expressions of premium intelligent mobility. Developed with a human-centered approach, FREELANDER 8 brings together digital interaction, physical controls and premium materials in a refined cabin environment that feels intuitive at every touch. Built on the brand’s three core product pillars — British Craftsmanship, Smart Confidence and All-Terrain Freedom, FREELANDER 8 offers a premium and intelligent cabin, a space designed for confidence, comfort and modern exploration. Continuing the classic elevated commander position on seat...

ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) — Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the pricing of its upsized initial public offering of 8,580,000 shares of its common stock at the high end of the range at a public offering price of $15.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $128.7 million. All shares of common stock to be sold in the offering will be sold by Scribe Therapeutics. In addition, Scribe Therapeutics has granted the underwriters a 30-day option to purchase up to an...

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) — Pelican Acquisition II Corporation (NASDAQ: PLCIU) (the “Company”), a Cayman Islands exempted company, announced that it priced its initial public offering of 7,500,000 units at $10.00 per unit on July 23, 2026. The units will be listed on the Nasdaq Capital Market (“NASDAQ”) and are expected to trade under the ticker symbol “PLCIU” beginning on July 24, 2026. Each unit consists of one ordinary share of the Company and one right, with each right entitling the holder thereof to receive one-tenth (1/10) of one ordinary share upon the consummation of an initial business combination.   Once the securities comprising the units begin separate trading, the ordinary shares and rights are expected to be listed on NASDAQ under the symbols “PLCI” and “PLCIR”, respectively. The offering is expected...